SCHEMBL5449405

SCHEMBL5449405

NC(=O)c1c(NC(=O)Nc2ccc(F)cc2)sc2c1CCC(=O)C2

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
MAPT P10636 2/20 0.58
ALDH1A1 P00352 1/20 0.58
GAA P10253 1/20 0.58
KCNH2 Q12809 10/20 0.54
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
TNIK Q9UKE5 1/20 0.48
KDM4E B2RXH2 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PTPN1 P18031 1/20 0.47
PTPRA P18433 1/20 0.47
EPHB4 P54760 1/20 0.45
ANO1 Q5XXA6 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17006411 0.90 KCNH2 (0.67) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5460151 0.89 KCNH2 (0.54) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5458794 0.89 KCNH2 (0.54) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5453526 0.88 KCNH2 (0.52) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5451566 0.87 FLT3 (0.56) KMT2AMEN1MAPTKCNH2NPC1
SCHEMBL5455183 0.86 FLT3 (0.55) KMT2AMEN1MAPTKCNH2RAB9A
SCHEMBL5460302 0.85 RAB9A (0.47) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5455065 0.85 MEN1 (0.79) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5447105 0.82 KMT2A (0.58) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL5457888 0.81 ANO1 (0.64) KMT2AMEN1MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KMT2A 4785/4885MEN1 2891/4885MAPT 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.